Depression treatment of elderly patients using tricyclics, MAOI, SSRI, and other antidepressants;Tratamento de idosos com depressão utilizando tricíclicos, IMAO, ISRS e outros antidepressivos

Revista Brasileira de Psiquiatria

Volumn 24, Issue SUPPL. 1, 2002, Pages 55-63

  Scalco, Mônica Z ^a,b,c,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Psychiatry ^*  (Canada)

^d BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

Aged; Antidepressive agents; Depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGING; ANOREXIA; ANXIETY; DEMENTIA; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; NAUSEA; RASH; REVIEW; RISK ASSESSMENT; SOMNOLENCE;

EID: 0036102946     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462002000500011     Document Type: Review

References (123)

1. Psychopharmacology
2. The biology of aging
3. Psychopharmacology ans aging
4. Orthostatic hypotension and anti-hypertensive therapy in the elderly
5. Major adverse reactions during desipramine treatment
6. Efficacy of acute treatment for geriatric depression
7. Pharmacological treatment of depression in elderly patients
8. Buspirone and imipramine for the treatment of major depression in the elderly
9. Clinical predictors of response to antidepressants in elderly patients
10. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly
11. Plasma levels and effects of nortriptyline in geriatric depressed patients
12. Pharmacological treatment of major depression for elderly patients in residential care settings
13. Nortriptyline side effects during double-blind, randomized, placebo-controlled maintenance therapy in older depressed patients
14. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias
15. Neural symptoms induced by tricyclic antidepressants: Phenomenology and patophysiology
16. Antidepressants and cognitive impairment in the elderly
17. The effect of Nortriptyline in elderly patients with cardiac conduction disease
18. Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline
19. Review of the cardiovascular effects of heterocyclic antidepressants
20. Tricyclic antidepressant and supine, standing, and exercise plasma norepinephrine levels
21. Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides vs elderly depressed normotensive women treated with nortriptyline
22. Cardiovascular effects of tricyclic antidepressants
23. Falls among older people: Relationship to medication use and orthostatic hypotension
24. Medicine in the elderly: Clinical presentation of orthostatic hypotension in the elderly
25. Syncope and orthostatic hypotension
26. Myocardial infarction caused by hypotension during physical examination maneuvers in the elderly
27. Orthostatic hypotension as a risk factor for symptomatic occlusive cerebrovascular disease
28. Incidence of orthostatic hypotension in patients with primary affective disordres treated with tricyclic antidepressant
29. Orthostatic effect of imipramine and doxepin in depressed geriatric outpatients
30. A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients
31. The use of imipramine in depressed patients with congestive heart failure
32. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness
33. Moclobemide in elderly patients with cognitive decline and depression: An international double-blind, placebo-controlled trial
34. Moclobemide and nortriptttyline in elderly depressed patients: A randomized, multicentre trial against placebo
35. A sequential double-blind controlled study of moclobemide and mianserine in elderly depressed patients
36. Moclobemide compared with second-generation antidepressants in elderly people
37. Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: A controlled comparative study versus imipramine
38. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients
39. Comparison of efficacy of moclobemida and fluvoxamina in elderly patients with a severe depressive episode
40. Moclobemide vs. Fluoxetine in elderly out-patients with major depression or dysthymia: A double blind-trial
41. Efficacy and Tolertability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: A clinical overview
42. Antidepressants and mood stabilizers
43. Fluoxetine collaborative study group: A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression
44. An overview of fluoxetine in geriatric depression
45. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression
46. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients
47. Comparison of sertraline and nortripttyline in the treatment of major depressive disorder in late life
48. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients
49. Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: An open multicentre study
50. Paroxetine in the elderly: A comparative meta-analysis against standard antidepressant pharmacotherapy
51. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6 Week outcome
52. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
53. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice
54. Fluoxetine and extrapyramidal side effects
55. Adverse reactions of antidepressants in elderly patients
56. Sintomas de interrupcion del tratamiento com antidepressivos: Enfoque de los inhibidores selectivosde la recaptacion de serotonina
57. Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review
58. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly
59. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports
60. Effect of fluoxetine on the eletrocardiogram
61. Bradycardia and syncope induced by fluoxetine in two patients
62. Bradycardia and syncope induced by fluoxetine
63. How safe are serotonin reuaptake inhibitors for depression in patients with coronary heart disease?
64. Pharmacokinetics of single and multiple-dose bupropion in elderly patients with depression
65. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly
66. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide
67. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients
68. Na open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients
69. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depresión
70. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders
71. Hyponatremia and selective serotonin reuptake inhibitors in elderly patients
72. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline
73. Evolutionary trends in the pharmacotherapeutic management of depression
74. The safety profile of nefazodone
75. A multicenter, double-blind comparison of nefazodone and maprotiline in the treatment of non-psychotic depressed aged (>60 years old) patients
76. The seletive alfa2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HTIA-mediated serotoninergic neurotransmission
77. Safety of mirtazapine: A review
78. Org3770 (Mirtazapine) versus trazodone: A placebo-controlled trial in depressed elderly patients
79. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients
80. Mirtazapine in elderly inpatients with somatic or neurological comorbidity
81. Treatment benefits of reboxetine
82. Reboxetine: A review of antidepressant tolerability
83. Reboxetine: Additional benefits to the depressed patient
84. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomized trial
85. Tianeptine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression
86. Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin
87. One-year open study of tianeptine in 140 elderly patients with depression
88. Pharmacokinetic considerations of antidepressant use in the elderly
89. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment
90. Clinically relevant pharmacology of seletive serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
91. Clinical pharmacokinetics of nefazodone
92. Steady-state pharmacokinetics of citalopram in young and elderly subjects
93. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression
94. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers
95. Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications
96. Clomipramine in the elderly: Tolerance and plasma levels
97. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
98. Inibição dose-dependente do CYP1A2, CYP2C19 e CYP2D6 pelo citalopram, fluoxetina, fluvoxamina e paroxetina
99. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
100. Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients
101. A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients
102. Placebo-controlled treatment trial of depression in elderly physically ill patients
103. Feasibility and effectiveness of treatments for depression in elderly medical inpatients: A systematic review
104. Tricyclic antidepressants in depressed patients with cardiac condution disease
105. Effective treatment of poststroke depression with serotonin selective reuptake inhibitor citalopram
106. Nortriptyline treatment of post-stroke depression: A double-blind study
107. Does fluoxetine exacerbate Parkinson's disease?
108. Drug treatment of depression in frail elderly nursing home residents
109. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients
110. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression
111. Diagnosos and treatment of depression in patients with Alzheimer's disease and other dementias
112. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders
113. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia
114. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study
115. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia
116. Fluvoxamine in the treatment of demented elderly patients: A double-blind, placebo-controlled study
117. Fluvoxamine treatment of dementia: Tryptofan levels
118. Fluoxetine in dementia of the Alzheimer's type: Proeminent adverse effects and failure to improve cognition
119. The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis
120. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
121. Discontinuation rates of SSRIs and tricyclic antidepressants: A meta-analysis and investigation of heterogeneity
122. Pharmacological and psychological treatments for depressed older patients: A meta-analysis and overview of recent findings
123. The effectiveness of antidepressants in elderly depressed outpatients: A prospective case series study